Skip to content

Study · Animal study (in vivo) · 2005

6 results

Feeding, body weight, and sensitivity to non-ingestive reward stimuli during and after 12-day continuous central infusions of melanocortin receptor ligands.

Cabeza de Vaca S, Hao J, Afroz T, Krahne LL, Carr KD

Peptides1 Nov 2005Cited by 12 (Europe PMC)

PMID15894406 (opens in a new tab)DOI10.1016/j.peptides.2005.03.041 (opens in a new tab)PepBankPUB-15894406
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Chronic intracerebroventricular MTII infusion produced a brief hypophagia of 3 days, followed by a return of daily food intake to control levels.

    In plain wordsMTII infused into the brain cut food intake for 3 days only; intake then returned to normal levels.

    Peptide
    Melanotan II
    Outcome
    MixedFood intake during 12-day infusion
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    The MCR agonist, MTII (0.02 microg/h) produced a brief hypophagia (3 days) followed by a return to control levels of daily intake
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    During the 12-day MTII infusion, body weight stayed at a reduced level.

    In plain wordsDuring MTII infusion into the brain, body weight stayed lower throughout the 12 days.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight during 12-day infusion
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    but with body weight remaining at a reduced level throughout the 12-day infusion period.
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    After the MTII infusion ended, compensatory hyperphagia occurred during the 24-day post-infusion period.

    In plain wordsAfter MTII infusion stopped, the animals ate more for a time to make up for earlier lower intake.

    Peptide
    Melanotan II
    Outcome
    IncreaseFood intake after MTII infusion (24-day post-infusion period)
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    This was followed by compensatory hyperphagia and weight gain during the 24-day post-infusion period.
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    After the MTII infusion ended, weight gain occurred during the 24-day post-infusion period.

    In plain wordsAfter MTII infusion stopped, the animals gained weight again over the following weeks.

    Peptide
    Melanotan II
    Outcome
    IncreaseBody weight after MTII infusion (24-day post-infusion period)
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    This was followed by compensatory hyperphagia and weight gain during the 24-day post-infusion period.
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    There was no change in sensitivity to non-ingestive reward stimuli during the infusion of MTII.

    In plain wordsDuring MTII infusion, the animals' response to non-food reward stimuli did not change.

    Peptide
    Melanotan II
    Outcome
    No significant changeSensitivity to rewarding stimulation during MTII infusion
    Study

    n: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    There was no change in sensitivity to non-ingestive reward stimuli during the infusion of MTII.
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    Sensitivity to D-amphetamine was increased during the 24-day period after the MTII infusion.

    In plain wordsAfter MTII infusion stopped, the animals became more sensitive to the reward effect of D-amphetamine.

    Peptide
    Melanotan II
    Outcome
    IncreaseSensitivity to D-amphetamine after MTII infusion
    Study

    n: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    0.02 microg/h · intracerebroventricular · 12 daysAs given in this study.

    Source sentences

    Summary
    There was no change in sensitivity to non-ingestive reward stimuli during the infusion of MTII. However, sensitivity to D-amphetamine was increased during the 24-day post-infusion period.
    1 context sentence
    Summary · context
    The objective of this study was to investigate effects of chronic i.c.v. infusion of the MCR agonist, MTII, and the MCR antagonist, SHU9119, on food intake, body weight, and sensitivity to rewarding lateral hypothalamic electrical stimulation (LHSS) and the reward-potentiating (i.e., threshold-lower…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.